Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab

Primary liver cancer is characterized by closely related with chronic inflammation, thereby reversing hypoxic immunosuppressive microenvironment of tumor cell growth immunotherapy drug a potentially effective strategy. Camrelizumab an anti-PD-1 antibody being developed Jiangsu Hengrui Pharmaceuticals Co., Ltd. We reported case adult critical Chinese patient primary hepatocellular carcinoma and lung metastasis completely responding to Camrelizumab, most the lesions were stable no new occurred after 1-year treatment, which provides us reconsider therapeutic effect on such patients. had safety profile for in our report, except occurrence RCCEP. This evidence antitumor activity manageable toxicities patients advanced carcinoma, was first application as far we know.